多发性硬化症治疗市场按药物类别、给药途径、分销管道和地区划分

2025 年全球多发性硬化症治疗市场规模估计为 313.9 亿美元，预计到 2032 年将达到 418.9 亿美元，2025 年至 2032 年的复合年增长率为 4.2%。

数字。 2025 年多发性硬化症治疗市场占有率（按地区划分）

多发性硬化症 (MS) 是一种影响中枢神经系统 (CNS) 的慢性自体免疫疾病。当免疫系统攻击髓鞘（包围中枢神经系统 (CNS) 神经纤维的保护鞘）时，就会发生多发性硬化症。结果导致大脑与身体其他部位之间的交流受损。症状可以从轻微到严重，取决于中枢神经系统病变的数量和位置。常见症状包括疲劳、手脚无力或麻木、失去协调性和平衡性、视力问题和认知障碍。多发性硬化症无法治疗方法，但干扰素、醋酸Glatiramer、单株抗体和皮质类固醇等药物疗法可以控制症状并减缓病情进展。

市场动态

全球多发性硬化症治疗市场的成长受到多种因素的推动，例如已开发国家和发展中国家多发性硬化症盛行率的增加、老年人口的增加、大量新型创新多发性硬化症治疗方法方法、医疗支出的激增以及报销计划的可用性。然而，多发性硬化症治疗的高成本可能会阻碍市场的成长。多发性硬化症治疗的个人化药物的出现、联合治疗、输注疗法和多发性硬化症治疗的口服药物的日益采用可以为市场成长提供机会。

研究的主要特点

本报告对全球多发性硬化症治疗市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。

它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。

它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。

全球多发性硬化症治疗市场的主要企业已根据公司亮点、产品系列、关键亮点、绩效和策略等参数进行了分析。

本研究涉及的主要企业包括 Biogen、Novartis、Merck、Sanofi、Teva Pharmaceuticals、Bayer、ACORDA THERAPEUTICS、CELGENE 等。

本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。

全球多发性硬化症治疗市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

相关人员将透过全球多发性硬化症治疗市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购情景

4. 2020 年至 2032 年全球多发性硬化症治疗市场（按药物类别划分）（十亿美元）

• 介绍
• β干扰素
• 皮质类固醇
• 单株抗体
• 抗肿瘤药物
• 其他的

5. 2020 年至 2032 年全球多发性硬化症治疗市场，依给药途径划分（十亿美元）

• 介绍
• 口服
• 注射
• 其他的

6. 2020-2032 年全球多发性硬化症治疗市场按分销管道划分（十亿美元）

• 介绍
• 医院药房
• 零售药局
• 网路药局

7. 2020 年至 2032 年全球多发性硬化症治疗市场（按地区划分）（十亿美元）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第八章 竞争格局

• Biogen Inc.
• Novartis AG
• Merck KGaA
• Sanofi SA
• Acorda Therapeutics, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bristol-Myers Squibb Company
• Bayer AG
• Hoffmann-La Roche AG
• Viatris Inc.（Mylan NV）
• Johnson & Johnson
• EMD Serono, Inc.
• TG Therapeutics, Inc.
• Genentech, Inc.
• Celgene Corporation
• AbbVie Inc.
• Amgen Inc.
• UCB SA
• 山德士（诺华旗下的一个部门）
• Ipsen SA

第 9 章分析师建议

• 兴衰
• 一致的机会地图

第十章参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Global Multiple Sclerosis Therapeutics Market is estimated to be valued at USD 31.39 Bn in 2025 and is expected to reach USD 41.89 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2032.

Figure. Multiple Sclerosis Therapeutics Market Share (%), By Region 2025

Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). It is caused when the immune system attacks myelin, the protective sheath surrounding nerve fibers of the CNS. The damage disrupts communication between the brain and other parts of the body. Symptoms can be mild or severe, depending on the number and location of lesions in the CNS. Common symptoms include fatigue, weakness or numbness in the limbs, poor coordination and balance, vision problems, and cognitive dysfunction. There has been no known cure for MS but medications such as interferons, glatiramer acetate, monoclonal antibodies, corticosteroids can manage the disease symptoms and slow down its progression.

Market Dynamics:

Global multiple sclerosis therapeutics market growth is driven by factors like increasing prevalence of multiple sclerosis across both developed and developing nations, growing geriatric population, robust pipeline of new and innovative treatment therapies for multiple sclerosis, surging healthcare spending, and availability of reimbursement schemes. However, high costs associated with multiple sclerosis drugs can hamper the market growth. Emergence of personalized medicines for multiple sclerosis treatment, growing adoption of combination therapies, infusion therapies, and oral drugs for multiple sclerosis treatment can offer market growth opportunities.

Key features of the study:

This report provides in-depth analysis of the global multiple sclerosis therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global multiple sclerosis therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS and CELGENE

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global multiple sclerosis therapeutics market

Detailed Segmentation-

• By Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agent
  • Others
• By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Injection
  • Others
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Biogen Inc.
  • Novartis AG
  • Merck KGaA
  • Sanofi S. A.
  • Acorda Therapeutics, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Hoffmann-La Roche AG
  • Viatris Inc. (Mylan NV)
  • Johnson & Johnson
  • EMD Serono, Inc.
  • TG Therapeutics, Inc.
  • Genentech, Inc.
  • Celgene Corporation
  • AbbVie Inc.
  • Amgen Inc.
  • UCB S.A.
  • Sandoz (a Novartis division)
  • Ipsen S.A.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Multiple Sclerosis Therapeutics Market, By Drug Class
  • Global Multiple Sclerosis Therapeutics Market, By Route of Administration
  • Global Multiple Sclerosis Therapeutics Market, By Distribution Channel
  • Global Multiple Sclerosis Therapeutics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Beta Interferon
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Monoclonal Antibodies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antineoplastic Agent
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Injection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Multiple Sclerosis Therapeutics Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Biogen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi S. A.
• Acorda Therapeutics, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bristol-Myers Squibb Company
• Bayer AG
• Hoffmann-La Roche AG
• Viatris Inc. (Mylan NV)
• Johnson & Johnson
• EMD Serono, Inc.
• TG Therapeutics, Inc.
• Genentech, Inc.
• Celgene Corporation
• AbbVie Inc.
• Amgen Inc.
• UCB S.A.
• Sandoz (a Novartis division)
• Ipsen S.A.

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us